Please login to the form below

Therapy Watch expands oncology and IBD portfolios

This month Therapy Watch expands its portfolio with the launch of several new trackers across numerous therapy areas including the launch of a new Chronic Myelogenous Leukaemia (CML) study in the US.

CML is a rare cancer affecting the white blood cells and accounts for only 20% of all leukaemias affecting adults. The new CML study will include a panel of Haematologists and Haemato-Oncologists reporting on CML patients every month, including both first-line and later-line patients, resulting in over 2000 patient record forms (PRFs).

Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer (PCa), Renal Cell Carcinoma (RCC) and Squamous Cell Carcinoma of the Head and Neck (SCCHN). 

Find out more 
https://www.researchpartnership.com/news/2017/06/therapy-watch-expands-oncology-and-ibd-portfolios/


5th July 2017

Share

Tags

Company Details

Research Partnership

+44 (0)20 8069 5000

Contact Website

Address:
Chester House
Fulham Green
81-83 Fulham High Street
London
SW6 3JW
United Kingdom

Latest content on this profile

RP Investigates - Virtual Q&A session:
Living with Lupus
Research Partnership
Webcast:
Demand assessment
Research Partnership
White paper:
Are we prepared for the influx of CAR-Ts?
Research Partnership
New syndicated patient report -
Living with Lupus US
Research Partnership
Video:
Emotion AI
Research Partnership
Report:
Mexico’s drug market access landscape shake-up: What does it mean for pharma?
Research Partnership